GlassScriptPhysician profile
Jennifer L Brenner
NPI 1417047671
$12,907.55
in general payments reported to CMS, 2019-2025
47 companies · $2,506 in 2025
The $2,506 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,240 · 2022: $2,456 · 2023: $2,078 · 2024: $2,627 · 2025: $2,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,111 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,110.88 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,824.96 | 2021-2025 | |
| Pfizer INC. | $532.99 | 2021-2025 | |
| Emd Serono, INC. | $508.27 | 2021-2025 | Mavenclad |
| Sk Life Science, INC. | $430.52 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $339.75 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $320.84 | 2021-2025 | Austedo, Austedo Xr, Ajovy |
| Biohaven Pharmaceutical Holding Company LTD. | $299.69 | 2022 | |
| Amgen INC. | $246.46 | 2021-2024 | Aimovig |
| Ucb, INC. | $238.67 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Biogen, INC. | $207.28 | 2021-2025 | Skyclarys, Leqembi, Vumerity |
| Lundbeck LLC | $193.94 | 2022-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $188.69 | 2021-2025 | |
| Genzyme Corporation | $178.32 | 2021-2025 | |
| Lilly USA, LLC | $168.38 | 2021-2025 | Kisunla, Emgality |
| Neurocrine Biosciences, INC. | $154.06 | 2022-2025 | Ingrezza, Ongentys |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $149.64 | 2021-2025 | Qelbree |
| Alexion Pharmaceuticals, INC. | $146.49 | 2022-2025 | Ultomiris |
| Harmony Biosciences LLC | $138.20 | 2025 | |
| Eisai INC. | $137.20 | 2024-2025 | |
| Mdd US Operations, LLC | $126.89 | 2022-2024 | Gocovri, Myobloc, Apokyn |
| Argenx US, INC. | $115.31 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Merck Sharp & Dohme LLC | $113.24 | 2021 | |
| Genentech USA, INC. | $105.77 | 2021-2024 | Ocrevus |
| Abbott Laboratories | $91.64 | 2024 | Infinity |
| Livanova USA, INC. | $88.18 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Ge Healthcare | $81.45 | 2022-2024 | |
| Kyowa Kirin, INC. | $75.78 | 2023-2024 | Nourianz |
| Amneal Pharmaceuticals LLC | $66.67 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $60.69 | 2025 | Xeomin, Ampyra, Inbrija |
| Tanabe Pharma America, INC. | $57.09 | 2021-2023 | |
| Avadel Cns Pharmaceuticals, LLC | $55.65 | 2024 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $47.45 | 2024-2025 | Hyqvia |
| Azurity Pharmaceuticals, INC. | $44.08 | 2025 | Zonisade |
| Janssen Pharmaceuticals, INC | $40.86 | 2022 | |
| Upsher-Smith Laboratories LLC | $33.01 | 2022 | |
| Jazz Pharmaceuticals INC. | $32.61 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $32.30 | 2023 | Trudhesa |
| Catalyst Pharmaceuticals, INC. | $31.27 | 2025 | |
| Acadia Pharmaceuticals INC | $28.34 | 2022-2023 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $27.20 | 2022 | |
| Fisher & Paykel Healthcare INC | $25.90 | 2025 | Fisher & Paykel Healthcare |
| E.R. Squibb & Sons, L.L.C. | $23.23 | 2021 | |
| Inspire Medical Systems, INC. | $22.60 | 2025 | Inspire |
| Acorda Therapeutics, INC | $21.82 | 2023 | Ampyra, Inbrija |
| Horizon Therapeutics Plc | $19.65 | 2021 | |
| Octapharma USA, INC. | $19.33 | 2024 | Panzyga |
| Otsuka America Pharmaceutical, INC. | $15.19 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.